Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 342, pseudogene (RNU6-342P) is classified as a **pseudogene** of the U6 small nuclear RNA family, specifically the 342nd annotated member. Pseudogenes are genomic DNA sequences similar to normal genes but non-functional; they do not encode functional products and typically lack regulatory elements required for expression[2][4][6]. U6 snRNA genes themselves code for essential components of the spliceosome and are involved in the splicing of pre-mRNA in eukaryotic cells[1][3], but **pseudogene copies such as RNU6-342P are generally not functional and do not contribute to canonical U6 snRNA activity or recognized biological pathways**[4][6]. **Pseudogenes can sometimes have regulatory roles at the RNA level, such as serving as potential sources of small regulatory RNAs or affecting cognate gene expression, but there is currently no information indicating that RNU6-342P is therapeutically actionable, associates with disease, or is a drug target**[2]. **Clarification**: - The queried "target" is **not a therapeutic target** such as a receptor, enzyme, or transporter. - The designation "pseudogene" makes it inherently non-protein-coding and non-functional in the canonical sense of a biological target[4][6]. - No disease, drug, or biomarker association is described for this locus. **Most other U6 pseudogenes share this lack of biological or therapeutic relevance**. There is nothing unique about RNU6-342P as a target, and the query as a therapeutic target is not appropriate. If you intended to ask about canonical U6 snRNA, which plays a critical cellular function in splicing, that is a distinct, functional non-coding RNA, not a pseudogene[1][3][5]. **Summary**: RNU6-342P is a U6 snRNA pseudogene, not a functional therapeutic target. The entry as a drug target, receptor, or enzyme is incorrect. All structured data fields appropriately reflect null or not applicable values for a pseudogene[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 342, pseudogene (RNU6-342P).